Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Care Rationing | 4 | 2021 | 435 | 2.020 |
Why?
|
Neoplasms | 16 | 2024 | 22142 | 1.210 |
Why?
|
Leukemia | 3 | 2024 | 1518 | 1.090 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2024 | 3610 | 1.050 |
Why?
|
Hematologic Neoplasms | 4 | 2024 | 1895 | 1.020 |
Why?
|
Cancer Care Facilities | 3 | 2024 | 422 | 0.940 |
Why?
|
Translating | 1 | 2022 | 143 | 0.750 |
Why?
|
Pharmaceutical Preparations | 2 | 2020 | 1086 | 0.740 |
Why?
|
Hematology | 1 | 2024 | 243 | 0.730 |
Why?
|
Pharmacists | 2 | 2020 | 259 | 0.690 |
Why?
|
Social Justice | 1 | 2024 | 477 | 0.640 |
Why?
|
Decision Making, Organizational | 1 | 2019 | 136 | 0.620 |
Why?
|
Resource Allocation | 1 | 2021 | 350 | 0.620 |
Why?
|
Hepatitis B | 1 | 2024 | 703 | 0.620 |
Why?
|
Medical Oncology | 5 | 2023 | 2320 | 0.600 |
Why?
|
Antineoplastic Agents | 8 | 2024 | 13632 | 0.600 |
Why?
|
Pharmacy Service, Hospital | 1 | 2019 | 134 | 0.600 |
Why?
|
State Government | 1 | 2021 | 384 | 0.590 |
Why?
|
Pharmacy | 1 | 2019 | 91 | 0.570 |
Why?
|
Climate Change | 2 | 2023 | 498 | 0.570 |
Why?
|
Standard of Care | 1 | 2021 | 550 | 0.560 |
Why?
|
Radiation Oncology | 1 | 2022 | 563 | 0.520 |
Why?
|
Clinical Trials as Topic | 4 | 2024 | 8002 | 0.500 |
Why?
|
Compassionate Use Trials | 1 | 2015 | 50 | 0.480 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 269 | 0.470 |
Why?
|
Health Services Accessibility | 2 | 2024 | 5426 | 0.460 |
Why?
|
Artificial Intelligence | 3 | 2024 | 2576 | 0.450 |
Why?
|
Neoplasm, Residual | 2 | 2019 | 1008 | 0.450 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 686 | 0.450 |
Why?
|
Ethics Committees, Clinical | 1 | 2014 | 56 | 0.450 |
Why?
|
Environmental Monitoring | 1 | 2020 | 1460 | 0.440 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2024 | 296 | 0.430 |
Why?
|
Patient Preference | 1 | 2020 | 927 | 0.410 |
Why?
|
Ethics, Medical | 2 | 2015 | 785 | 0.410 |
Why?
|
Neutrophils | 1 | 2024 | 3763 | 0.380 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2019 | 940 | 0.370 |
Why?
|
Patient Selection | 2 | 2020 | 4246 | 0.360 |
Why?
|
Health Policy | 1 | 2022 | 2679 | 0.350 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 419 | 0.340 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3634 | 0.330 |
Why?
|
Epidemics | 1 | 2015 | 512 | 0.320 |
Why?
|
Decision Making | 3 | 2024 | 3931 | 0.300 |
Why?
|
Clinical Protocols | 1 | 2014 | 1436 | 0.300 |
Why?
|
Telemedicine | 1 | 2024 | 3051 | 0.280 |
Why?
|
Humans | 47 | 2024 | 761222 | 0.270 |
Why?
|
Vaccines | 1 | 2015 | 835 | 0.260 |
Why?
|
Ethics Consultation | 2 | 2024 | 59 | 0.250 |
Why?
|
Myelodysplastic Syndromes | 3 | 2021 | 1393 | 0.250 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4014 | 0.240 |
Why?
|
Azacitidine | 2 | 2017 | 336 | 0.240 |
Why?
|
Greenhouse Effect | 1 | 2024 | 31 | 0.240 |
Why?
|
Duffy Blood-Group System | 1 | 2024 | 58 | 0.230 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26072 | 0.230 |
Why?
|
United States | 10 | 2024 | 72341 | 0.220 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7400 | 0.220 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2164 | 0.220 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2017 | 646 | 0.210 |
Why?
|
Physicians | 2 | 2024 | 4584 | 0.210 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5665 | 0.200 |
Why?
|
Antiviral Agents | 1 | 2015 | 3048 | 0.200 |
Why?
|
Bilirubin | 1 | 2024 | 436 | 0.200 |
Why?
|
Analgesics, Opioid | 1 | 2018 | 3805 | 0.200 |
Why?
|
Certification | 1 | 2024 | 418 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 420 | 0.180 |
Why?
|
Hematologic Diseases | 1 | 2024 | 496 | 0.180 |
Why?
|
Leukocyte Count | 1 | 2024 | 1597 | 0.180 |
Why?
|
Melanoma | 2 | 2018 | 5694 | 0.180 |
Why?
|
Patient Rights | 1 | 2021 | 126 | 0.170 |
Why?
|
Mutation | 4 | 2020 | 30004 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 858 | 0.170 |
Why?
|
Environmental Health | 1 | 2022 | 289 | 0.170 |
Why?
|
Illinois | 1 | 2020 | 120 | 0.170 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 206 | 0.170 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.170 |
Why?
|
Aged | 15 | 2024 | 169292 | 0.160 |
Why?
|
Pharmacies | 1 | 2021 | 168 | 0.160 |
Why?
|
Hospitals, University | 1 | 2020 | 565 | 0.150 |
Why?
|
Environment | 1 | 2024 | 1122 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 375 | 0.150 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 934 | 0.150 |
Why?
|
Politics | 1 | 2024 | 814 | 0.150 |
Why?
|
Survival Rate | 3 | 2022 | 12728 | 0.140 |
Why?
|
HIV Infections | 1 | 2024 | 17348 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11733 | 0.140 |
Why?
|
Adult | 13 | 2024 | 221120 | 0.140 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2018 | 430 | 0.140 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 780 | 0.130 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 569 | 0.130 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2756 | 0.130 |
Why?
|
Male | 19 | 2024 | 360703 | 0.130 |
Why?
|
Middle Aged | 15 | 2024 | 220858 | 0.120 |
Why?
|
Africa, Western | 1 | 2015 | 159 | 0.120 |
Why?
|
Health Services Misuse | 1 | 2016 | 244 | 0.120 |
Why?
|
Patient Care | 1 | 2020 | 623 | 0.120 |
Why?
|
Terminal Care | 2 | 2024 | 1760 | 0.120 |
Why?
|
Minority Groups | 1 | 2021 | 1201 | 0.110 |
Why?
|
Sulfonamides | 1 | 2023 | 1977 | 0.110 |
Why?
|
Acute Disease | 1 | 2024 | 7226 | 0.110 |
Why?
|
Female | 18 | 2024 | 392552 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2020 | 2425 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2024 | 80675 | 0.100 |
Why?
|
Internet | 1 | 2024 | 3096 | 0.100 |
Why?
|
Anemia | 1 | 2021 | 1504 | 0.100 |
Why?
|
Health Services Research | 1 | 2019 | 1807 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1385 | 0.090 |
Why?
|
Massachusetts | 1 | 2024 | 8837 | 0.090 |
Why?
|
Injections | 1 | 2014 | 832 | 0.090 |
Why?
|
Advance Care Planning | 1 | 2018 | 697 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12474 | 0.080 |
Why?
|
World Health Organization | 1 | 2015 | 1321 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3354 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4739 | 0.080 |
Why?
|
Developing Countries | 1 | 2021 | 2863 | 0.080 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 609 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2018 | 10756 | 0.070 |
Why?
|
Survival Analysis | 2 | 2018 | 10088 | 0.070 |
Why?
|
Drug Industry | 1 | 2014 | 788 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10218 | 0.070 |
Why?
|
Bone Marrow | 1 | 2016 | 2911 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2915 | 0.070 |
Why?
|
Germ-Line Mutation | 1 | 2014 | 1852 | 0.060 |
Why?
|
Palliative Care | 1 | 2021 | 3599 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2021 | 58952 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2011 | 1372 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3808 | 0.060 |
Why?
|
Intensive Care Units | 1 | 2016 | 3744 | 0.050 |
Why?
|
Prognosis | 3 | 2020 | 29688 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5333 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2020 | 4822 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13367 | 0.040 |
Why?
|
Internship and Residency | 1 | 2020 | 5885 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5783 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2020 | 64681 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 59222 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2023 | 6819 | 0.040 |
Why?
|
Remission Induction | 1 | 2023 | 2392 | 0.040 |
Why?
|
Chicago | 1 | 2018 | 254 | 0.040 |
Why?
|
Algorithms | 1 | 2018 | 14025 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2019 | 782 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2020 | 5666 | 0.030 |
Why?
|
Hospitalization | 1 | 2016 | 10707 | 0.030 |
Why?
|
5-Methylcytosine | 1 | 2016 | 148 | 0.030 |
Why?
|
Anthraquinones | 1 | 1995 | 41 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17897 | 0.020 |
Why?
|
Formamides | 1 | 1989 | 21 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18384 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2507 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10516 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8642 | 0.020 |
Why?
|
Drugs, Investigational | 1 | 1989 | 212 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 1651 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6486 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4537 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11119 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4107 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 1990 | 1007 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8519 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54437 | 0.010 |
Why?
|
Recurrence | 1 | 2017 | 8457 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14675 | 0.010 |
Why?
|
Pyrazoles | 1 | 1995 | 2010 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15841 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5301 | 0.010 |
Why?
|
Drug Evaluation | 2 | 1990 | 641 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13511 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1995 | 1624 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 1990 | 362 | 0.010 |
Why?
|
Risk Factors | 1 | 2016 | 74241 | 0.010 |
Why?
|
Half-Life | 1 | 1990 | 649 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 88300 | 0.000 |
Why?
|
Infusions, Intravenous | 1 | 1990 | 2217 | 0.000 |
Why?
|
Administration, Oral | 1 | 1989 | 4015 | 0.000 |
Why?
|
Drug Administration Schedule | 1 | 1989 | 4851 | 0.000 |
Why?
|
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(36)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_